– USA, NJ – IVERIC bio, Inc. (Nasdaq: ISEE) today announced the election of Dr. Pravin U. Dugel (MD) to its Board of Directors, effective as of January 1, 2023.
“We are excited to have Pravin join our board during this pivotal time as the Company prepares for a potential approval and commercial launch of ACP in geographic atrophy,” said Board Chair, Dr. Adrienne Graves.
CEO Glenn Sblendorio added, “Pravin is an exceptional leader whose skills as an executive and extensive knowledge as a retinal specialist provide a valued perspective that will enhance the collective experience of our Board. I enjoy working closely with Pravin and now look forward to working with him in his added role as a board member. We are committed to executing our plan to deliver value to our shareholders.”
About Dr. Pravin U. Dugel
Dr. Dugel has been instrumental in helping to shape the Company’s business strategy and overseeing the development and regulatory submission process for avacincaptad pegol since he joined Iveric Bio in 2020.
“I look forward to adding to my responsibilities by serving as a board member of the Company. I am particularly honored to be among this group of talented and diverse board members,” said Dr. Pravin Dugel. “Following the successful results from our Phase 3 ACP clinical trials, I believe we have the potential to transform the AMD treatment landscape by bringing a breakthrough therapy to patients impacted by geographic atrophy.”
Dr. Dugel is currently the President of Iveric Bio. He joined as EVP in April 2020 and was promoted to President of the Company in May 2021. Dr. Dugel has over 26 years of experience as a retina specialist. Dr. Dugel was previously Managing Partner, at Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, at USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona. Dr. Dugel has authored more than 200 papers, and 35 book chapters and has been invited to lecture at several marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada, and Australia. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology. He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the Board of Directors of the largest retina society in the United States, the American Society of Retina Specialists, and the largest retina society in Europe, EURETINA.
Dr. Dugel graduated summa cum laude from Columbia University in New York City. He then attended UCLA School of Medicine. He completed his residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. After that, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he was elected to serve on the faculty as the Resident Director.
About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe, and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration.
For more information: https://ivericbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.